Anthrax - Pipeline Review, H1 2014

  • Share on Google+

Global Markets Direct

2014 Jun 30

152 Pages (PDF)

Anthrax - Pipeline Review, H1 2014


Global Markets Directs, Anthrax - Pipeline Review, H1 2014, provides an overview of the Anthraxs therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Anthrax
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anthrax and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anthrax pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anthrax
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anthrax Overview 8
Therapeutics Development 9
Pipeline Products for Anthrax - Overview 9
Pipeline Products for Anthrax - Comparative Analysis 10
Anthrax - Therapeutics under Development by Companies 11
Anthrax - Therapeutics under Investigation by Universities/Institutes 15
Anthrax - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Anthrax - Products under Development by Companies 20
Anthrax - Products under Investigation by Universities/Institutes 22
Anthrax - Companies Involved in Therapeutics Development 23
Bristol-Myers Squibb Company 23
Aradigm Corporation 24
Bavarian Nordic A/S 25
Emergent BioSolutions Inc. 26
Grifols, S.A. 27
The Medicines Company 28
Oragenics, Inc. 29
Soligenix, Inc. 30
Elusys Therapeutics, Inc. 31
Green Cross Corporation 32
Summit Corporation plc 33
Evolva SA 34
Protein Potential, LLC 35
ProThera Biologics, LLC. 36
MacroGenics, Inc. 37
Planet Biotechnology Inc. 38
Vaxin, Inc. 39
Microbiotix, Inc. 40
NanoBio Corporation 41
Immunovaccine, Inc. 42
iBio, Inc. 43
Cellceutix Corporation 44
Tetraphase Pharmaceuticals Inc. 45
Hawaii Biotech, Inc. 46
PaxVax 47
Pfenex Inc. 48
SelectX Pharmaceuticals, Inc. 49
Revivicor, Inc. 50
Navigen Pharmaceuticals, Inc. 51
Innovative Biologics, Inc. 52
ContraFect Corporation 53
PsiOxus Therapeutics, Ltd. 54
Conkwest, Inc. 55
Anthrax - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 68
ETI-204 - Drug Profile 68
NP-015 - Drug Profile 70
AV-7909 - Drug Profile 71
GC-1109 - Drug Profile 72
PreviThrax - Drug Profile 73
MDX-1303 - Drug Profile 74
AVP-21D9 - Drug Profile 76
Anthrax Vaccine - Drug Profile 77
ARD-1100 - Drug Profile 78
ARD-3100 - Drug Profile 79
MVA-BN Anthrax - Drug Profile 81
MU-1140 - Drug Profile 82
EV-021 - Drug Profile 84
oritavancin disphosphate - Drug Profile 85
CST-102 - Drug Profile 87
PMX-30016 - Drug Profile 88
AdVAV Anthrax Vaccine - Drug Profile 89
SMT-15000 - Drug Profile 91
Subunit Vaccine For Anthrax - Drug Profile 92
Monoclonal Antibody For Respiratory Anthrax - Drug Profile 93
Anthrax Vaccine - Drug Profile 94
Px-563L - Drug Profile 95
TP-271 - Drug Profile 96
PolyMap - Drug Profile 97
anthrax vaccine - Drug Profile 98
Subunit Vaccine for Anthrax - Drug Profile 99
Small Molecules to Inhibit MMP - Drug Profile 100
Human Antibody Based Vaccines - Drug Profile 101
Subunit Vaccine For Anthrax-Plague Combination - Drug Profile 103
SGX-204 - Drug Profile 104
Anthrax Program - Drug Profile 105
GREANX - Drug Profile 106
W1-mAb - Drug Profile 107
Live Attenuated Vaccine for Anthrax - Drug Profile 108
IAIP - Drug Profile 109
PBI-220 - Drug Profile 110
Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 111
Small Molecules for Bacterial Infections - Drug Profile 112
anthrax vaccine next generation - Drug Profile 113
KKL-35 - Drug Profile 114
Small Molecules Inhibiting Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 115
Slit2N - Drug Profile 116
Bifunctional Antibiotics for Anthrax and Cystic Fibrosis - Drug Profile 118
CF-308 - Drug Profile 119
CF-307 - Drug Profile 120
Anthrax - Recent Pipeline Updates 121
Anthrax - Dormant Projects 139
Anthrax - Discontinued Products 140
Anthrax - Product Development Milestones 141
Featured News & Press Releases 141
Appendix 148
Methodology 148
Coverage 148
Secondary Research 148
Primary Research 148
Expert Panel Validation 148
Contact Us 149
Disclaimer 149
Bristol-Myers Squibb Company 
Aradigm Corporation 
Bavarian Nordic A/S 
Emergent BioSolutions Inc. 
Grifols, S.A. 
The Medicines Company 
Oragenics, Inc. 
Soligenix, Inc. 
Elusys Therapeutics, Inc. 
Green Cross Corporation 
Summit Corporation plc 
Evolva SA 
Protein Potential, LLC 
ProThera Biologics, LLC. 
MacroGenics, Inc. 
Planet Biotechnology Inc. 
Vaxin, Inc. 
Microbiotix, Inc. 
NanoBio Corporation 
Immunovaccine, Inc. 
iBio, Inc. 
Cellceutix Corporation 
Tetraphase Pharmaceuticals Inc. 
Hawaii Biotech, Inc. 
Pfenex Inc. 
SelectX Pharmaceuticals, Inc. 
Revivicor, Inc. 
Navigen Pharmaceuticals, Inc. 
Innovative Biologics, Inc. 
ContraFect Corporation 
PsiOxus Therapeutics, Ltd. 
Conkwest, Inc.				
Full Name
Job Title
Your Requirement
Full Name
Job Title
Your Requirement